The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
July 11th 2025
States have expanded access to over-the-counter ivermectin, raising concerns among health experts about safety, misinformation, and self-medication risks.
Helping Baltimoreans Safely Dispose of Medication
November 12th 2018On Wednesday, October 24, and Saturday, October 27, student pharmacists from the University of Maryland School of Pharmacy chapter of the APhA-ASP joined forces with the University of Maryland, Baltimore Police and the Drug Enforcement Administration (DEA) to host our bi-annual Drug Take-Back Day at the University’s SMC Campus Center.
Read More
DarioHealth's Digital Diabetes Platform to be Made Available to 4.6 Million Customers at Giant Eagle
November 12th 2018DarioHealth Corp., a leading global digital health company with mobile health and big data solutions, has announced that it has signed an agreement for the rollout of a Digital Diabetes Education and Rewards Program to Giant Eagle's consumers through the pharmacy's 214 locations.
Read More
The Pharmacist's Transition to USP 800
November 8th 2018In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for University at Buffalo's patient safety organization Empire State Patient Safety Assurance Network, explains the challenges pharmacists will face in transitioning to USP800.
Watch
The Challenges of USP 800 for Compounding Pharmacies
November 8th 2018In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for University at Buffalo's patient safety organization Empire State Patient Safety Assurance Network, explains the challenges compounding pharmacies will face with USP800.
Watch
New Immunotherapy Combination Granted FDA Approval for Certain Adults with Multiple Myeloma
November 7th 2018Officials with the FDA have approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of certain patients with relapsed or refractory multiple myeloma.
Read More
FDA Grants Priority Review for Dupilumab as Potential Treatment for Atopic Dermatitis in Adolescents
November 6th 2018The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.
Read More
FDA Grants Accelerated Approval to Lorlatinib for ALK+ NSCLC
November 4th 2018The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors.
Read More